NCT02337764View on ClinicalTrials.gov

A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

PHASE3CompletedINTERVENTIONAL

Enrollment

222

Participants

Timeline

Start Date

February 3, 2015

Primary Completion Date

September 29, 2016

Study Completion Date

September 29, 2016

Conditions

Parkinson's Disease

Interventions

DRUG

TVP-1012 1mg

TVP-1012 1mg Tablets

Trial Locations (24)

Unknown

Nagoya

Matsuyama

Fukuoka

Kōriyama

Sapporo

Himeji

Kobe

Sanda

Tsuchiura

Ichinoseki

Kawasaki

Sagamihara

Yokohama

Tenri

Shimajiri-gun

Chuo-ku

Meguro-ku

Shinjuku-ku

Fukuoka

Kochi

Kyoto

Miyazaki

Osaka

Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY